{"id":36461,"date":"2026-11-16T17:21:53","date_gmt":"2026-11-16T11:51:53","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=36461"},"modified":"2026-11-16T17:21:57","modified_gmt":"2026-11-16T11:51:57","slug":"neuroendocrine-carcinoma-treatment-landscape","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/neuroendocrine-carcinoma-treatment-landscape","title":{"rendered":"Neuroendocrine Carcinoma: After Four Decades of Chemo, the Treatment Playbook Is Changing"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_85 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6afba8845c6f6\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6afba8845c6f6\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/neuroendocrine-carcinoma-treatment-landscape\/#Neuroendocrine_Carcinoma_A_Rare_Cancer_That_Moves_Fast\" >Neuroendocrine Carcinoma: A Rare Cancer That Moves Fast<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/neuroendocrine-carcinoma-treatment-landscape\/#Pulmonary_NECSCLC_and_Extrapulmonary_NEC_Two_Faces_of_One_Aggressive_Disease\" >Pulmonary NEC\/SCLC and Extrapulmonary NEC: Two Faces of One Aggressive Disease<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/neuroendocrine-carcinoma-treatment-landscape\/#Neuroendocrine_Carcinoma_Treatment_Today_Whats_Actually_Approved\" >Neuroendocrine Carcinoma Treatment Today: What&#8217;s Actually Approved?<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/neuroendocrine-carcinoma-treatment-landscape\/#Amgens_IMDELLTRA_The_T-Cell_Engager_That_Changed_the_Conversation\" >Amgen&#8217;s IMDELLTRA: The T-Cell Engager That Changed the Conversation<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/neuroendocrine-carcinoma-treatment-landscape\/#Chugais_TECENTRIQ_The_Immunotherapy_That_Opened_the_Door_in_Japan\" >Chugai&#8217;s TECENTRIQ: The Immunotherapy That Opened the Door in Japan<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/neuroendocrine-carcinoma-treatment-landscape\/#Incytes_ZYNYZ_A_PD-1_Option_for_a_Neuroendocrine_Skin_Cancer\" >Incyte&#8217;s ZYNYZ: A PD-1 Option for a Neuroendocrine Skin Cancer<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/neuroendocrine-carcinoma-treatment-landscape\/#AstraZenecas_IMFINZI_Finally_Progress_in_Limited-Stage_Disease\" >AstraZeneca&#8217;s IMFINZI: Finally, Progress in Limited-Stage Disease<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/neuroendocrine-carcinoma-treatment-landscape\/#Pharma_Mar_and_Jazz_Pharmaceuticals_ZEPZELCA_Rewriting_First-Line_Maintenance\" >Pharma Mar and Jazz Pharmaceuticals&#8217; ZEPZELCA: Rewriting First-Line Maintenance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.delveinsight.com\/blog\/neuroendocrine-carcinoma-treatment-landscape\/#Nippon_Kayakus_CALSED_Japans_Long-Standing_Second-Line_Workhorse\" >Nippon Kayaku&#8217;s CALSED: Japan&#8217;s Long-Standing Second-Line Workhorse<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/www.delveinsight.com\/blog\/neuroendocrine-carcinoma-treatment-landscape\/#The_Neuroendocrine_Carcinoma_Pipeline_DLL3_B7-H3_and_the_Race_for_Whats_Next\" >The Neuroendocrine Carcinoma Pipeline: DLL3, B7-H3 and the Race for What&#8217;s Next<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/www.delveinsight.com\/blog\/neuroendocrine-carcinoma-treatment-landscape\/#DLL3_Beyond_IMDELLTRA_A_Crowded_and_Fast-Moving_Field\" >DLL3 Beyond IMDELLTRA: A Crowded and Fast-Moving Field<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/www.delveinsight.com\/blog\/neuroendocrine-carcinoma-treatment-landscape\/#B7-H3_and_the_Ifinatamab_Deruxtecan_Setback\" >B7-H3 and the Ifinatamab Deruxtecan Setback<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/www.delveinsight.com\/blog\/neuroendocrine-carcinoma-treatment-landscape\/#Neuroendocrine_Carcinoma_Market_Outlook_Where_the_Growth_Is_Coming_From\" >Neuroendocrine Carcinoma Market Outlook: Where the Growth Is Coming From<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/www.delveinsight.com\/blog\/neuroendocrine-carcinoma-treatment-landscape\/#Conclusion_From_Few_Options_to_a_Field_in_Motion\" >Conclusion: From Few Options to a Field in Motion<\/a><\/li><\/ul><\/nav><\/div>\n\n<p><strong><em>Summary<\/em><\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><em>SCLC is the core of the NEC market. Small cell lung cancer makes up roughly 10-15% of lung cancers, with about 250,000 new cases worldwide each year, and most patients are diagnosed at the extensive stage.<\/em><\/li>\n\n\n\n<li><em>Extrapulmonary NEC is the biggest unmet need. With an incidence of about 1 per 100,000, it has no standard second-line therapy, and real-world first-line survival is only about 9 months.<\/em><\/li>\n\n\n\n<li><em>Approved options have grown fast. IMDELLTRA (full FDA approval Nov 2025), IMFINZI (limited-stage, Dec 2024), and ZEPZELCA plus atezolizumab (first-line maintenance, Oct 2025) have each added a new standard of care since 2024.<\/em><\/li>\n\n\n\n<li><em>The emerging NEC pipeline is increasingly focused on DLL3- and B7-H3-directed therapies, ADCs, bispecific T-cell engagers, and innovative immunotherapy combinations aimed at improving survival, overcoming treatment resistance, and expanding therapeutic options for patients with SCLC and epNEC.<\/em><\/li>\n\n\n\n<li><em>Key candidates under clinical evaluation include Zai Lab\u2019s Zocilurtatug Pelitecan (ZL-1310), GSK\u2019s Risvutatug Rezetecan (GSK5764227), Pfizer\u2019s PF-08634404, Boehringer Ingelheim\u2019s Obrixtamig, Bristol Myers Squibb\u2019s Pumitamig, AbbVie\u2019s ABBV-706, Phanes Therapeutics\u2019 Peluntamig (PT217), IDEAYA Biosciences\u2019 IDE849, Merck\/Daiichi Sankyo\u2019s Gocatamig (MK-6070), and others.<\/em><\/li>\n<\/ul>\n\n\n\n<p>For most of the last four decades, a diagnosis of neuroendocrine carcinoma meant the same thing: platinum-etoposide chemotherapy, a fast response, and a relapse that arrived faster than anyone hoped. That script is finally being rewritten. T-cell engagers, antibody-drug conjugates, and new maintenance strategies are pulling one of oncology&#8217;s most neglected cancers into the spotlight, and the pace of change since 2024 has been remarkable.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-neuroendocrine-carcinoma-a-rare-cancer-that-moves-fast\"><span class=\"ez-toc-section\" id=\"Neuroendocrine_Carcinoma_A_Rare_Cancer_That_Moves_Fast\"><\/span><strong>Neuroendocrine Carcinoma: A Rare Cancer That Moves Fast<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Neuroendocrine carcinoma (NEC) is the high-grade, poorly differentiated end of the neuroendocrine neoplasm spectrum. Under the microscope, it is defined by rapid cell division: a Ki-67 proliferation index above 20% and a high mitotic count are the classic hallmarks. Pathologists confirm the diagnosis with markers such as synaptophysin, chromogranin A, CD56, and INSM1, and NECs are typically split into small-cell and large-cell types. The biology explains the clinical picture. NECs grow quickly, spread early, and tend to respond well to chemotherapy at first, then recur, usually more resistant than before. That pattern holds whether the tumor starts in the lung or elsewhere in the body.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-pulmonary-nec-sclc-and-extrapulmonary-nec-two-faces-of-one-aggressive-disease\"><span class=\"ez-toc-section\" id=\"Pulmonary_NECSCLC_and_Extrapulmonary_NEC_Two_Faces_of_One_Aggressive_Disease\"><\/span><strong>Pulmonary NEC\/SCLC and Extrapulmonary NEC: Two Faces of One Aggressive Disease<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>In practice, NEC falls into two groups that share biology but differ sharply in size, evidence, and treatment options.<\/p>\n\n\n\n<p><strong>Pulmonary NEC, led by small cell lung cancer (SCLC)<\/strong><\/p>\n\n\n\n<p>SCLC is itself a high-grade neuroendocrine carcinoma, and it is by far the largest <a href=\"https:\/\/www.delveinsight.com\/report-store\/neuroendocrine-carcinoma-epidemiology-forecast\">NEC population<\/a>. It accounts for roughly <strong>10-15% of all lung cancers<\/strong>. DelveInsight estimates that about <strong>250,000<\/strong> people are diagnosed with SCLC worldwide each year, including roughly <strong>27,000<\/strong> in the US in 2025, or about 12% of US lung cancers. The burden is heavy because the disease is usually found late. Most patients present with extensive-stage disease (ES-SCLC), and Amgen has noted that fewer than 3% of ES-SCLC patients live beyond five years. Limited-stage disease makes up roughly <strong>30%<\/strong> of diagnoses, and it too recurs often despite chemoradiation. Smoking is the dominant risk factor, which also means many patients arrive with other smoking-related illnesses that complicate treatment.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"334\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/Neuroendocrine-Carcinoma-Patient-Pool-Analysis-1024x334.webp\" alt=\"Neuroendocrine-Carcinoma-Patient-Pool-Analysis\" class=\"wp-image-36466\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/Neuroendocrine-Carcinoma-Patient-Pool-Analysis-1024x334.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/Neuroendocrine-Carcinoma-Patient-Pool-Analysis-300x98.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/Neuroendocrine-Carcinoma-Patient-Pool-Analysis-150x49.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/Neuroendocrine-Carcinoma-Patient-Pool-Analysis-768x250.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/Neuroendocrine-Carcinoma-Patient-Pool-Analysis-1536x501.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/Neuroendocrine-Carcinoma-Patient-Pool-Analysis.webp 1920w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p><strong>Extrapulmonary NEC (epNEC)<\/strong><\/p>\n\n\n\n<p>Extrapulmonary NEC can arise almost anywhere: the gastrointestinal tract (the most common site in several published series), the bladder, the cervix, the skin (as Merkel cell carcinoma), and more. It is much rarer than SCLC, with an incidence of about <strong>1 per 100,000 people<\/strong>, according to a 2026 real-world analysis presented at ASCO. Rarity brings its own problem: very little high-quality evidence. Platinum-etoposide is borrowed from SCLC and remains the consensus first-line standard, while no second-line standard is agreed upon. In that <a href=\"https:\/\/www.delveinsight.com\/asco-conference-2026\">ASCO 2026<\/a> US real-world dataset, first-line patients had a median overall survival of just 9.0 months, and only 7.0 months among those treated with platinum-etoposide alone. One widely cited retrospective review reports median survival of around five months once the disease reaches distant sites.<\/p>\n\n\n\n<p>For patients and the companies serving them, the message is the same. Both groups face an aggressive cancer, a short window for treatment, and a long-standing shortage of options. That shortage is exactly what makes the current wave of innovation so significant.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-neuroendocrine-carcinoma-treatment-today-what-s-actually-approved\"><span class=\"ez-toc-section\" id=\"Neuroendocrine_Carcinoma_Treatment_Today_Whats_Actually_Approved\"><\/span><strong>Neuroendocrine Carcinoma Treatment Today: What&#8217;s Actually Approved?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The honest answer is that almost everything approved for neuroendocrine carcinoma is approved for small cell lung cancer. Extrapulmonary NEC patients borrow those regimens and the platinum-etoposide backbone, because dedicated labels for their disease barely exist.&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-amgen-s-imdelltra-the-t-cell-engager-that-changed-the-conversation\"><span class=\"ez-toc-section\" id=\"Amgens_IMDELLTRA_The_T-Cell_Engager_That_Changed_the_Conversation\"><\/span><strong>Amgen&#8217;s IMDELLTRA: The T-Cell Engager That Changed the Conversation<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>IMDELLTRA (tarlatamab-dlle)<\/strong> is a bispecific T-cell engager that links DLL3 on tumor cells to CD3 on T cells, steering the patient&#8217;s own immune system toward the cancer. The FDA first cleared it in May 2024 under accelerated approval, based on the <strong>phase 2 DeLLphi-301 study<\/strong>: a 40% objective response rate, a 9.7-month median duration of response and a 14.3-month median overall survival in heavily pretreated patients.<\/p>\n\n\n\n<p>The confirmatory <strong>phase 3 DeLLphi-304 trial<\/strong> (509 patients) then showed that tarlatamab cut the risk of death by about 40% compared with standard chemotherapy, with fewer dose reductions or discontinuations for side effects. That earned full FDA approval on November 19, 2025, and European Commission approval followed on June 1, 2026. The label carries a boxed warning for cytokine release syndrome and neurologic toxicity, including ICANS, so monitoring logistics matter.<\/p>\n\n\n\n<p>The bigger story is moving earlier. In the phase 3 DeLLphi-305 trial (563 patients), adding tarlatamab to durvalumab as first-line maintenance lifted median overall survival to 21.1 months from 12.7 months with durvalumab alone (hazard ratio 0.42). The data were presented at ESMO 2026 and published in the New England Journal of Medicine. This use is not yet approved, and Amgen has said it will share the results with regulators.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-chugai-s-tecentriq-the-immunotherapy-that-opened-the-door-in-japan\"><span class=\"ez-toc-section\" id=\"Chugais_TECENTRIQ_The_Immunotherapy_That_Opened_the_Door_in_Japan\"><\/span><strong>Chugai&#8217;s TECENTRIQ: The Immunotherapy That Opened the Door in Japan<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>When Chugai won Japanese approval for <strong>TECENTRIQ (atezolizumab) <\/strong>in <a href=\"https:\/\/www.delveinsight.com\/report-store\/extensive-stage-small-cell-lung-cancer-market\">extensive-stage SCL treatment<\/a> on August 22, 2019, it became the first cancer immunotherapy cleared for the disease there and the first new option in 17 years. The approval, in combination with carboplatin and etoposide, rested on the IMpower133 study. TECENTRIQ remains central today, and not only in Japan. It is the partner drug in the ZEPZELCA maintenance combination, and a subcutaneous formulation (<strong>TECENTRIQ HYBREZA<\/strong>) is covered by the US label for that use.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"554\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/Marketed-Neuroendocrine-Carcinoma-Therapies-Roadmap-1024x554.webp\" alt=\"Marketed-Neuroendocrine-Carcinoma-Therapies-Roadmap\" class=\"wp-image-36467\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/Marketed-Neuroendocrine-Carcinoma-Therapies-Roadmap-1024x554.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/Marketed-Neuroendocrine-Carcinoma-Therapies-Roadmap-300x162.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/Marketed-Neuroendocrine-Carcinoma-Therapies-Roadmap-150x81.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/Marketed-Neuroendocrine-Carcinoma-Therapies-Roadmap-768x415.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/Marketed-Neuroendocrine-Carcinoma-Therapies-Roadmap-1536x830.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/Marketed-Neuroendocrine-Carcinoma-Therapies-Roadmap.webp 1920w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-incyte-s-zynyz-a-pd-1-option-for-a-neuroendocrine-skin-cancer\"><span class=\"ez-toc-section\" id=\"Incytes_ZYNYZ_A_PD-1_Option_for_a_Neuroendocrine_Skin_Cancer\"><\/span><strong>Incyte&#8217;s ZYNYZ: A PD-1 Option for a Neuroendocrine Skin Cancer<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>ZYNYZ (retifanlimab-dlwr) <\/strong>is not an SCLC drug, which makes it easy to overlook. But Merkel cell carcinoma (MCC) is a neuroendocrine carcinoma of the skin, and in extrapulmonary NEC it is one of the few subtypes with a dedicated PD-1 label. The FDA approved ZYNYZ for metastatic or recurrent locally advanced MCC in March 2023, based on the single-arm PODIUM-201 study. The European Commission followed in April 2024 with a first-line monotherapy indication for patients not suited to curative surgery or radiation.<\/p>\n\n\n\n<p>The FDA expanded the <a href=\"https:\/\/www.delveinsight.com\/blog\/zynyz-for-anal-cancer\">ZYNYZ label<\/a> in May 2025 to include squamous cell carcinoma of the anal canal, but that is a separate tumor type. For NEC watchers, the takeaway is that checkpoint inhibition has a proven foothold outside the lung, and MCC patients have historically fared better than other extrapulmonary NEC groups.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-astrazeneca-s-imfinzi-finally-progress-in-limited-stage-disease\"><span class=\"ez-toc-section\" id=\"AstraZenecas_IMFINZI_Finally_Progress_in_Limited-Stage_Disease\"><\/span><strong>AstraZeneca&#8217;s IMFINZI: Finally, Progress in Limited-Stage Disease<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Limited-stage SCLC had seen little innovation for decades until the <strong>ADRIATIC trial<\/strong>. The FDA approved <strong>IMFINZI (durvalumab)<\/strong> on December 4, 2024, for adults whose LS-SCLC had not progressed after concurrent platinum chemotherapy and radiation. In 730 patients, durvalumab reduced the risk of death by 27% (median OS 55.9 vs 33.4 months) and extended median progression-free survival to 16.6 months from 9.2 months. The European Commission approved it in 2025.<\/p>\n\n\n\n<p>IMFINZI is also approved with chemotherapy in extensive-stage disease based on the <strong>CASPIAN trial<\/strong>, which makes it the immunotherapy backbone across both stages. Pneumonitis, including radiation pneumonitis, is the main safety watch-out after chemoradiation. IMFINZI is also the foundation of the DeLLphi-305 regimen described above.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-pharma-mar-and-jazz-pharmaceuticals-zepzelca-rewriting-first-line-maintenance\"><span class=\"ez-toc-section\" id=\"Pharma_Mar_and_Jazz_Pharmaceuticals_ZEPZELCA_Rewriting_First-Line_Maintenance\"><\/span><strong>Pharma Mar and Jazz Pharmaceuticals&#8217; ZEPZELCA: Rewriting First-Line Maintenance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>ZEPZELCA (lurbinectedin)<\/strong> is an alkylating agent that binds DNA. The FDA first approved it in June 2020 for metastatic SCLC after platinum chemotherapy, and its second act has been bigger. On October 2, 2025, the FDA approved ZEPZELCA plus atezolizumab as <a href=\"https:\/\/www.delveinsight.com\/report-store\/extensive-stage-small-cell-lung-cancer-market\">first-line maintenance for ES-SCLC patients<\/a> who had not progressed after atezolizumab, carboplatin, and etoposide induction.<\/p>\n\n\n\n<p>In the phase 3 IMforte trial, the combination reduced the risk of progression or death by 46% (median PFS 5.4 vs 2.1 months) and the risk of death by 27% (median OS 13.2 vs 10.6 months) compared with atezolizumab alone. The NCCN added it as a preferred regimen. The European Commission approved it on June 1, 2026, after Swissmedic and the UK&#8217;s MHRA. Myelosuppression is the key toxicity: 84% of IMforte patients received primary G-CSF prophylaxis.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-nippon-kayaku-s-calsed-japan-s-long-standing-second-line-workhorse\"><span class=\"ez-toc-section\" id=\"Nippon_Kayakus_CALSED_Japans_Long-Standing_Second-Line_Workhorse\"><\/span><strong>Nippon Kayaku&#8217;s CALSED: Japan&#8217;s Long-Standing Second-Line Workhorse<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>CALSED (amrubicin)<\/strong> is a synthetic anthracycline that inhibits topoisomerase II. It reached the Japanese market in 2002, and Nippon Kayaku has marketed it since January 2005 under license from <strong>Sumitomo<\/strong>. For years it was permitted for relapsed SCLC only in Japan, and a meta-analysis of 803 patients suggested it compares favorably with topotecan, though with heavy hematologic toxicity (about 70% grade 3-4 neutropenia and 12% febrile neutropenia). Amrubicin still matters globally as a reference point: it is one of the physician&#8217;s-choice chemotherapy comparators in the phase 3 IDeate-Lung02 trial. In Japan, a study of 150 patients found that its efficacy held up after prior chemoimmunotherapy, which keeps it relevant in the second-line setting.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-the-neuroendocrine-carcinoma-pipeline-dll3-b7-h3-and-the-race-for-what-s-next\"><span class=\"ez-toc-section\" id=\"The_Neuroendocrine_Carcinoma_Pipeline_DLL3_B7-H3_and_the_Race_for_Whats_Next\"><\/span><strong>The Neuroendocrine Carcinoma Pipeline: DLL3, B7-H3 and the Race for What&#8217;s Next<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>If the approved landscape is the present, the neuroendocrine carcinoma treatment pipeline is where the field is placing its bets. Two targets dominate: DLL3, reported on the surface of up to 85% of SCLC tumors, and B7-H3, an immune-regulating protein that is overexpressed in many cancers. Around them, developers are testing bispecific and trispecific T-cell engagers, antibody-drug conjugates (ADCs), CAR-T cells, and radionuclide conjugates. ADCs aimed at Trop2 and SEZ6 are also moving forward. A useful reality check comes from a 2026 MD Anderson preprint. In 138 SCLC patients, DLL3 expression by immunohistochemistry was heterogeneous, with a median of 70%, and higher expression tracked with better outcomes on tarlatamab. Biomarker selection is likely to matter as this class grows.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-dll3-beyond-imdelltra-a-crowded-and-fast-moving-field\"><span class=\"ez-toc-section\" id=\"DLL3_Beyond_IMDELLTRA_A_Crowded_and_Fast-Moving_Field\"><\/span><strong>DLL3 Beyond IMDELLTRA: A Crowded and Fast-Moving Field<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/blog\/rise-of-dll3-targeted-therapies-in-neuroendocrine-cancers\">DLL3-targeted therapeutic pipeline<\/a> for small-cell lung cancer (SCLC) and extrapulmonary neuroendocrine carcinoma (epNEC) includes several promising candidates across different stages of development. Key candidates include <strong>Zocilurtatug pelitecan<\/strong> (ZL-1310; Zai Lab Limited), Obrixtamig (Boehringer Ingelheim), <strong>BL-M14D1<\/strong> (SystImmune), <strong>Gocatamig <\/strong>(MK-6070; Merck\/Daiichi Sankyo), <strong>Peluntamig <\/strong>(PT217; Phanes Therapeutics), <strong>IDE849 <\/strong>(IDEAYA Biosciences), <strong>Clesitamig <\/strong>(RO7616789; Roche\/Chugai Pharmaceutical), and others. Among these, <strong>obrixtamig <\/strong>is the only candidate currently being evaluated in the first-line setting for epNEC, while the others primarily target relapsed or platinum-refractory disease, addressing a major unmet need.<\/p>\n\n\n\n<p><em>Sadaf Javed, Functional Head of Forecasting &amp; Analytics at DelveInsight, said that emerging DLL3-targeted agents, including zocilurtatug pelitecan, are expected to gain market share as biomarker-driven treatment options with the potential to improve outcomes in both pulmonary and extrapulmonary NEC.<\/em><\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"364\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/Competitive-Landscape-of-Emerging-Neuroendocrine-Carcinoma-Drugs-1024x364.webp\" alt=\"Competitive-Landscape-of-Emerging-Neuroendocrine-Carcinoma-Drugs\" class=\"wp-image-36468\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/Competitive-Landscape-of-Emerging-Neuroendocrine-Carcinoma-Drugs-1024x364.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/Competitive-Landscape-of-Emerging-Neuroendocrine-Carcinoma-Drugs-300x107.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/Competitive-Landscape-of-Emerging-Neuroendocrine-Carcinoma-Drugs-150x53.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/Competitive-Landscape-of-Emerging-Neuroendocrine-Carcinoma-Drugs-768x273.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/Competitive-Landscape-of-Emerging-Neuroendocrine-Carcinoma-Drugs-1536x546.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/Competitive-Landscape-of-Emerging-Neuroendocrine-Carcinoma-Drugs.webp 1920w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-b7-h3-and-the-ifinatamab-deruxtecan-setback\"><span class=\"ez-toc-section\" id=\"B7-H3_and_the_Ifinatamab_Deruxtecan_Setback\"><\/span><strong>B7-H3 and the Ifinatamab Deruxtecan Setback<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>Ifinatamab deruxtecan (I-DXd)<\/strong>, from <strong>Daiichi Sankyo and Merck<\/strong>, targets B7-H3 and looked like the next approval. It showed a 48.2% response rate in the <strong>Phase 2 IDeate-Lung01 trial<\/strong>, and the FDA granted priority review in April 2026 with an October 10, 2026 decision date. Interstitial lung disease or pneumonitis occurred in 12.4% of patients, which is the main safety issue to manage.<\/p>\n\n\n\n<p>Then, on September 25, 2026, the companies voluntarily withdrew the US application. After talks with the FDA, the phase 2 dataset was judged insufficient for accelerated approval in the post-platinum setting. Development continues: the <strong>phase 3 IDeate-Lung02 trial<\/strong>, comparing I-DXd with physician&#8217;s choice of amrubicin, lurbinectedin or topotecan, is still enrolling, and the companies say it is near completion.<\/p>\n\n\n\n<p>The lesson is strategic. With tarlatamab now fully approved on survival data, the regulatory bar for new second-line SCLC agents has risen. Single-arm response rates may no longer be enough.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-neuroendocrine-carcinoma-market-outlook-where-the-growth-is-coming-from\"><span class=\"ez-toc-section\" id=\"Neuroendocrine_Carcinoma_Market_Outlook_Where_the_Growth_Is_Coming_From\"><\/span><strong>Neuroendocrine Carcinoma Market Outlook: Where the Growth Is Coming From<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/report-store\/neuroendocrine-carcinoma-market\">Pulmonary NEC\/SCLC and EP-NEC (excluding NEPC) markets<\/a> are undergoing a gradual transformation, driven by growing disease awareness, improved diagnostic capabilities, expanding clinical research, and increasing adoption of immunotherapy and targeted treatment approaches. Historically, platinum-based chemotherapy has remained the cornerstone of treatment across these aggressive neuroendocrine malignancies.&nbsp;<\/p>\n\n\n\n<p>However, the integration of immune checkpoint inhibitors and the emergence of novel targeted therapies are progressively reshaping the therapeutic landscape. Recent approvals, including durvalumab (IMFINZI) in limited-stage small cell lung cancer (LS-SCLC) and tarlatamab (IMDELLTRA) in relapsed extensive-stage SCLC (ES-SCLC), have expanded treatment options and addressed longstanding unmet medical needs. Similarly, immune checkpoint inhibitors are increasingly being incorporated into EP-NEC treatment strategies for selected patients, although outcomes remain poor, underscoring the substantial need for more effective therapies.<\/p>\n\n\n\n<p>The treatment landscape across both markets is increasingly shifting toward biomarker-driven and targeted therapeutic approaches, with <a href=\"https:\/\/www.delveinsight.com\/report-store\/delta-like-ligand-3-targeted-therapies-market-forecast\">DLL3-targeted agents<\/a>, antibody-drug conjugates (ADCs), bispecific T-cell engagers, and novel immunotherapy combinations demonstrating promising potential, particularly in relapsed or refractory disease. Ongoing clinical development, including the expansion of DLL3-targeted therapies into earlier treatment settings and the advancement of innovative therapeutic modalities, is expected to broaden treatment options and improve clinical outcomes.&nbsp;<\/p>\n\n\n\n<p>Overall, increasing disease recognition, growing adoption of immunotherapy, advances in precision medicine, and continued pipeline innovation are anticipated to support sustained growth across the Pulmonary NEC\/SCLC and EP-NEC (excluding NEPC) markets, creating significant opportunities for established pharmaceutical companies and emerging biotechnology developers.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-conclusion-from-few-options-to-a-field-in-motion\"><span class=\"ez-toc-section\" id=\"Conclusion_From_Few_Options_to_a_Field_in_Motion\"><\/span><strong>Conclusion: From Few Options to a Field in Motion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Neuroendocrine carcinoma is still one of the hardest cancers to treat, but the story has changed. In under three years, SCLC has gained a T-cell engager with a confirmed survival benefit, an immunotherapy for limited-stage disease, and a new first-line maintenance combination. A second maintenance contender, tarlatamab plus durvalumab, has just posted a hazard ratio of 0.42 and is headed to regulators.<\/p>\n\n\n\n<p>Three takeaways stand out. First, DLL3 has been validated as a target, and the race to build on it now spans bispecifics, trispecifics, ADCs, CAR-T, and <a href=\"https:\/\/www.delveinsight.com\/blog\/radioligand-therapies-in-cancer-treatment\">radioligands<\/a>. Second, the bar is rising: the I-DXd withdrawal is a reminder that response rates alone no longer win approval. Third, extrapulmonary NEC remains the largest gap, with first-line survival around nine months and no standard second-line option, but fast-track designations suggest that gap is starting to attract serious investment.<\/p>\n\n\n\n<p>For clinicians, investors and strategists, the next 12 to 24 months will be decisive: regulatory decisions on first-line maintenance, the IDeate-Lung02 readout, and the first dedicated epNEC trials. Whoever tracks those milestones closely will understand where this market is going before it gets there.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/neuroendocrine-carcinoma-market\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/Neuroendocrine-Carcinoma-Market-Outlook-1024x194.webp\" alt=\"Neuroendocrine Carcinoma Market Outlook\" class=\"wp-image-36463\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/Neuroendocrine-Carcinoma-Market-Outlook-1024x194.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/Neuroendocrine-Carcinoma-Market-Outlook-300x57.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/Neuroendocrine-Carcinoma-Market-Outlook-150x28.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/Neuroendocrine-Carcinoma-Market-Outlook-768x145.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/Neuroendocrine-Carcinoma-Market-Outlook-1536x291.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/Neuroendocrine-Carcinoma-Market-Outlook.webp 1584w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Summary For most of the last four decades, a diagnosis of neuroendocrine carcinoma meant the same thing: platinum-etoposide chemotherapy, a fast response, and a relapse that arrived faster than anyone hoped. That script is finally being rewritten. T-cell engagers, antibody-drug conjugates, and new maintenance strategies are pulling one of oncology&#8217;s most neglected cancers into the [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":36464,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[23190,23189,23187,23184,23186,23185,23188],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-36461","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-ep-nec","tag-extrapulmonary-neuroendocrine-carcinoma","tag-nec-treatment","tag-neuroendocrine-carcinoma","tag-neuroendocrine-carcinoma-drugs","tag-neuroendocrine-carcinoma-treatment","tag-pilmonary-neuroendocrine-carcinoma","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.9 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>The New Era of Neuroendocrine Carcinoma Treatment<\/title>\n<meta name=\"description\" content=\"Emerging NEC treatment pipeline is increasingly focused on DLL3- and B7-H3-directed therapies, ADCs, and bispecific T-cell engagers.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/neuroendocrine-carcinoma-treatment-landscape\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The New Era of Neuroendocrine Carcinoma Treatment\" \/>\n<meta property=\"og:description\" content=\"Emerging NEC treatment pipeline is increasingly focused on DLL3- and B7-H3-directed therapies, ADCs, and bispecific T-cell engagers.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/neuroendocrine-carcinoma-treatment-landscape\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-16T11:51:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-16T11:51:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/neuroendocrine-carcinoma-treatment-landscape.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"12 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"The New Era of Neuroendocrine Carcinoma Treatment","description":"Emerging NEC treatment pipeline is increasingly focused on DLL3- and B7-H3-directed therapies, ADCs, and bispecific T-cell engagers.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/neuroendocrine-carcinoma-treatment-landscape","og_locale":"en_US","og_type":"article","og_title":"The New Era of Neuroendocrine Carcinoma Treatment","og_description":"Emerging NEC treatment pipeline is increasingly focused on DLL3- and B7-H3-directed therapies, ADCs, and bispecific T-cell engagers.","og_url":"https:\/\/www.delveinsight.com\/blog\/neuroendocrine-carcinoma-treatment-landscape","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2026-11-16T11:51:53+00:00","article_modified_time":"2026-11-16T11:51:57+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/neuroendocrine-carcinoma-treatment-landscape.webp","type":"image\/webp"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.delveinsight.com\/blog\/neuroendocrine-carcinoma-treatment-landscape#article","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/neuroendocrine-carcinoma-treatment-landscape"},"author":{"name":"Sandeep Joshi","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"headline":"Neuroendocrine Carcinoma: After Four Decades of Chemo, the Treatment Playbook Is Changing","datePublished":"2026-11-16T11:51:53+00:00","dateModified":"2026-11-16T11:51:57+00:00","mainEntityOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/neuroendocrine-carcinoma-treatment-landscape"},"wordCount":2378,"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/neuroendocrine-carcinoma-treatment-landscape#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/neuroendocrine-carcinoma-treatment-landscape.webp","keywords":["EP-NEC","Extrapulmonary Neuroendocrine Carcinoma","NEC Treatment","Neuroendocrine Carcinoma","Neuroendocrine Carcinoma Drugs","Neuroendocrine Carcinoma Treatment","Pilmonary Neuroendocrine Carcinoma"],"articleSection":["Articles"],"inLanguage":"en-US","copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/www.delveinsight.com\/blog\/#organization"}},{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/neuroendocrine-carcinoma-treatment-landscape","url":"https:\/\/www.delveinsight.com\/blog\/neuroendocrine-carcinoma-treatment-landscape","name":"The New Era of Neuroendocrine Carcinoma Treatment","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/neuroendocrine-carcinoma-treatment-landscape#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/neuroendocrine-carcinoma-treatment-landscape#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/neuroendocrine-carcinoma-treatment-landscape.webp","datePublished":"2026-11-16T11:51:53+00:00","dateModified":"2026-11-16T11:51:57+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Emerging NEC treatment pipeline is increasingly focused on DLL3- and B7-H3-directed therapies, ADCs, and bispecific T-cell engagers.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/neuroendocrine-carcinoma-treatment-landscape"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/neuroendocrine-carcinoma-treatment-landscape#primaryimage","url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/neuroendocrine-carcinoma-treatment-landscape.webp","contentUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/neuroendocrine-carcinoma-treatment-landscape.webp","width":466,"height":284,"caption":"neuroendocrine-carcinoma-treatment-landscape"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/neuroendocrine-carcinoma-treatment-landscape-300x183.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">EP-NEC<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Extrapulmonary Neuroendocrine Carcinoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">NEC Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Neuroendocrine Carcinoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Neuroendocrine Carcinoma Drugs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Neuroendocrine Carcinoma Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pilmonary Neuroendocrine Carcinoma<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">EP-NEC<\/span>","<span class=\"advgb-post-tax-term\">Extrapulmonary Neuroendocrine Carcinoma<\/span>","<span class=\"advgb-post-tax-term\">NEC Treatment<\/span>","<span class=\"advgb-post-tax-term\">Neuroendocrine Carcinoma<\/span>","<span class=\"advgb-post-tax-term\">Neuroendocrine Carcinoma Drugs<\/span>","<span class=\"advgb-post-tax-term\">Neuroendocrine Carcinoma Treatment<\/span>","<span class=\"advgb-post-tax-term\">Pilmonary Neuroendocrine Carcinoma<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 hours ago","modified":"Updated 8 hours ago"},"absolute_dates":{"created":"Posted on Nov 16, 2026","modified":"Updated on Nov 16, 2026"},"absolute_dates_time":{"created":"Posted on Nov 16, 2026 5:21 pm","modified":"Updated on Nov 16, 2026 5:21 pm"},"featured_img_caption":"neuroendocrine-carcinoma-treatment-landscape","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/36461","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=36461"}],"version-history":[{"count":2,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/36461\/revisions"}],"predecessor-version":[{"id":36469,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/36461\/revisions\/36469"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/36464"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=36461"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=36461"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=36461"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=36461"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=36461"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}